Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer

Diana Lüftner, Michael P Lux, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Milena Beierlein, Erik Belleville, Michael Untch, Marc Thill, Nina Ditsch, Bahriye Aktas, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Achim Wöckel, Hans-Christian KolbergNadia Harbeck, Elmar Stickeler, Hans Tesch, Andreas D Hartkopf


Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Issue number03
Pages (from-to)299-309
Number of pages11
Publication statusPublished - 03.2023

Research Areas and Centers

  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)
  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer'. Together they form a unique fingerprint.

Cite this